Alembic Pharmaceuticals quarterly results and financials

Alembic Pharmaceuticals (APLLTD)₹1,017+0.72%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (consolidated), Alembic Pharmaceuticals reported sales of ₹2,144 Cr, up 25.6% from Jun 2025, and net profit of ₹172 Cr, up 11.5% year on year. For the year to Mar 2026, sales were ₹7,321 Cr and net profit ₹671 Cr.

Sales (Jun 2026): ₹2,144 Cr
Net profit (Jun 2026): ₹172 Cr
Sales (FY Mar 2026): ₹7,321 Cr
Net profit (FY Mar 2026): ₹671 Cr
EPS (Jun 2026): ₹8.77
Borrowings (Mar 2026): ₹1,431 Cr

Company filings, consolidated accounts; latest reported quarter Jun 2026

Alembic Pharmaceuticals quarterly results

₹ crore unless stated; each column is a quarter.

Alembic Pharmaceuticals Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	1,590	1,626	1,514	1,557	1,642	1,688	1,766	1,706	1,905	1,871	1,842	2,144
Expenses	1,390	1,367	1,260	1,328	1,410	1,435	1,500	1,434	1,598	1,588	1,624	1,822
Operating Profit	208	266	260	237	239	260	271	281	316	292	228	332
OPM %	13.0%	16.0%	17.0%	14.9%	15.0%	15.0%	15.0%	16.0%	17.0%	16.0%	11.9%	14.9%
Other Income	9.99	3.01	4.01	1.99	29.99	10.01	13.99	5.99	7.99	−26.98	1.99	15.01
Interest	15.97	14.98	10.98	12.99	18.98	21.98	24.96	23.96	23.99	22.97	22.98	27.96
Depreciation	67.80	68.77	68.81	68.80	70.75	69.82	68.82	73.79	75.76	79.79	88.66	97.72
Profit before tax	135	184	182	156	179	177	192	189	223	161	119	221
Tax %	−1.0%	2.0%	3.0%	14.1%	15.1%	23.1%	18.0%	19.0%	18.0%	18.1%	−69.9%	22.1%
Exceptional items	0.00	0.00	0.00	0.00	10.01	0.00	0.00	0.00	0.00	−34.09	−18.03	0.00
Net Profit	137	180	178	135	153	138	157	154	184	132	202	172
EPS (Rs)	6.93	9.15	9.05	6.83	7.78	7.02	7.95	7.82	9.37	6.74	10.28	8.77

Alembic Pharmaceuticals profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Alembic Pharmaceuticals Profit and loss
	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	3,158	3,094	3,121	3,924	4,591	5,378	5,294	5,633	6,217	6,659	7,321	7,762
Expenses	2,161	2,493	2,493	3,068	3,386	3,920	4,443	4,979	5,309	5,671	6,240	6,632
Operating Profit	1,007	614	643	873	1,222	1,479	873	682	931	1,008	1,121	1,167
OPM %	32.0%	20.0%	20.9%	22.0%	26.9%	27.0%	16.0%	11.9%	15.0%	15.0%	14.9%	15.0%
Other Income	6.99	2.01	6.99	8.99	−38.99	87.02	55.95	−2.01	28.01	55.95	−13.99	−1.99
Interest	4.99	4.99	2.99	17.97	26.96	15.97	17.99	49.93	55.91	78.88	93.94	97.90
Depreciation	71.75	82.75	105	115	157	183	286	274	272	278	318	342
Profit before tax	932	527	539	747	997	1,364	623	354	630	705	692	724
Tax %	23.0%	23.1%	22.1%	21.1%	20.1%	19.1%	17.1%	4.0%	3.0%	18.0%	3.0%	—
Exceptional items	0.00	0.00	4.01	2.01	−33.04	5.01	3.01	−4.01	3.01	20.04	−56.08	−52.12
Net Profit	719	403	413	583	800	1,146	521	342	616	582	671	689
EPS (Rs)	38.08	21.32	21.81	30.89	43.83	58.13	26.42	17.35	31.26	29.58	34.22	35.16
Dividend payout %	9.0%	19.0%	18.0%	18.1%	23.0%	24.0%	38.1%	46.0%	35.0%	37.0%	35.1%	—

Alembic Pharmaceuticals balance sheet

₹ crore, at each year end.

Alembic Pharmaceuticals Balance sheet
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	38.14	38.15	38.15	38.11	38.14	38.15	39.12	39.15	39.15	39.15	39.14	39.15
Reserves	846	1,561	1,863	2,176	2,674	3,175	5,017	5,188	4,329	4,780	5,150	5,629
Borrowings	264	114	89.12	707	1,127	1,748	584	717	723	514	1,260	1,431
Other Liabilities	495	721	701	1,018	935	1,027	1,063	1,173	1,095	1,119	1,331	1,666
Total Liabilities	1,643	2,433	2,690	3,939	4,774	5,988	6,703	7,118	6,187	6,453	7,780	8,765
Fixed Assets	547	709	800	994	1,158	1,553	1,788	1,798	2,398	2,548	2,524	3,081
CWIP	82.66	92.71	394	1,005	1,544	1,838	2,174	2,296	599	522	834	680
Investments	2.01	87.11	50.09	42.05	49.05	18.03	236	118	96.08	93.05	127	141
Other Assets	1,011	1,545	1,446	1,898	2,022	2,579	2,505	2,905	3,092	3,289	4,295	4,863
Inventories	382	569	632	732	965	1,185	1,483	1,606	1,472	1,641	2,281	2,505
Trade receivables	360	349	338	524	488	863	348	805	1,043	1,023	1,396	1,462
Cash & equivalents	26.91	450	159	89.72	205	80.69	106	68.79	81.70	127	89.70	202
Total Assets	1,643	2,433	2,690	3,939	4,774	5,988	6,703	7,118	6,187	6,453	7,780	8,765

Alembic Pharmaceuticals cash flow

₹ crore, for each year.

Alembic Pharmaceuticals Cash flow
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	172	949	330	313	813	449	1,466	553	725	804	88.16	784
Cash from investing activity	−256	−307	−485	−884	−755	−731	−839	−371	−448	−321	−568	−506
Cash from financing activity	86.97	−224	−129	503	58.98	155	−597	−217	−262	−438	444	−164
Net cash flow	2.99	417	−286	−68.97	115	−127	25.99	−36.96	13.98	44.96	−36.95	113
Capex	224	0.00	0.00	822	764	735	659	426	443	327	564	495
Free cash flow	−51.88	645	347	−494	48.84	−284	801	128	281	486	−465	289
CFO / OP %	60.1%	114.0%	73.1%	70.1%	112.1%	56.1%	115.1%	77.1%	115.0%	88.1%	16.1%	79.0%

Alembic Pharmaceuticals ratios

Working-capital days and returns, by year.

Alembic Pharmaceuticals Ratios
	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	63	39	39	60	44	68	23	55	67	59	76	72
Inventory days	195	265	268	301	355	416	430	405	314	349	465	461
Days payable	166	264	213	313	237	220	194	178	145	157	179	154
Cash conversion cycle	94	42	96	51	164	266	261	283	237	253	363	381
Working capital days	31	35	60	68	23	49	72	73	76	87	86	86
ROCE %	38.1%	66.1%	29.1%	22.1%	23.1%	24.1%	26.1%	11.1%	7.0%	13.1%	13.1%	13.1%

Alembic Pharmaceuticals: frequently asked questions

What are the latest quarterly results of Alembic Pharmaceuticals?

For the Jun 2026 quarter, Alembic Pharmaceuticals reported sales of ₹2,144 Cr, up 25.6% year on year and net profit of ₹172 Cr, up 11.5% year on year. The operating margin was 14.9%.

What is the annual revenue of Alembic Pharmaceuticals?

Alembic Pharmaceuticals' sales for the year to Mar 2026 were ₹7,321 Cr; over the last twelve months they were ₹7,762 Cr.

What is the net profit of Alembic Pharmaceuticals?

Net profit for the year to Mar 2026 was ₹671 Cr, and ₹689 Cr over the last twelve months. Earnings per share over the same trailing period were ₹35.16.

How much debt does Alembic Pharmaceuticals have?

Alembic Pharmaceuticals reported borrowings of ₹1,431 Cr at Mar 2026, against cash and equivalents of ₹202 Cr.

What is the free cash flow of Alembic Pharmaceuticals?

Cash from operations was ₹784 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹289 Cr.

Loading…